Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 180

1.

A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease.

Vahabnezhad E, Rabizadeh S, Dubinsky MC.

Inflamm Bowel Dis. 2014 Apr;20(4):606-13. doi: 10.1097/MIB.0000000000000003.

3.

Efficacy and safety of infliximab in treating patients with ulcerative colitis: experiences from a single medical center in southern China.

Zhou YL, Xie S, Wang P, Zhang T, Lin MY, Tan JS, Zhi FC, Jiang B, Chen Y.

J Dig Dis. 2014 Sep;15(9):483-90. doi: 10.1111/1751-2980.12161.

PMID:
24828856
4.

Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study.

Steenholdt C, Molazahi A, Ainsworth MA, Brynskov J, Østergaard Thomsen O, Seidelin JB.

Scand J Gastroenterol. 2012 May;47(5):518-27. doi: 10.3109/00365521.2012.660541. Epub 2012 Mar 1.

PMID:
22375898
5.

Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease.

Singh N, Rosenthal CJ, Melmed GY, Mirocha J, Farrior S, Callejas S, Tripuraneni B, Rabizadeh S, Dubinsky MC.

Inflamm Bowel Dis. 2014 Oct;20(10):1708-13. doi: 10.1097/MIB.0000000000000137.

PMID:
25153505
6.

The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab.

Ungar B, Chowers Y, Yavzori M, Picard O, Fudim E, Har-Noy O, Kopylov U, Eliakim R, Ben-Horin S; ABIRISK consortium.

Gut. 2014 Aug;63(8):1258-64. doi: 10.1136/gutjnl-2013-305259. Epub 2013 Sep 16.

PMID:
24041539
7.

The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease.

Hoekman DR, Brandse JF, de Meij TG, Hummel TZ, Löwenberg M, Benninga MA, D'Haens GR, Kindermann A.

Scand J Gastroenterol. 2015;50(9):1110-7. doi: 10.3109/00365521.2015.1027264. Epub 2015 Apr 11.

PMID:
25865965
8.

Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease.

Bortlik M, Duricova D, Malickova K, Machkova N, Bouzkova E, Hrdlicka L, Komarek A, Lukas M.

J Crohns Colitis. 2013 Oct;7(9):736-43. doi: 10.1016/j.crohns.2012.10.019. Epub 2012 Nov 29.

PMID:
23200919
9.

Predictors of response to Infliximab in children with luminal Crohn's disease.

Grover Z, Biron R, Carman N, Lewindon P.

J Crohns Colitis. 2014 Aug;8(8):739-46. doi: 10.1016/j.crohns.2013.12.017. Epub 2014 Jan 18.

PMID:
24445015
10.

Extent of Early Clinical Response to Infliximab Predicts Long-term Treatment Success in Active Ulcerative Colitis.

Murthy SK, Greenberg GR, Croitoru K, Nguyen GC, Silverberg MS, Steinhart AH.

Inflamm Bowel Dis. 2015 Sep;21(9):2090-6. doi: 10.1097/MIB.0000000000000474.

PMID:
26099066
11.

Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.

Gisbert JP, Marín AC, McNicholl AG, Chaparro M.

Aliment Pharmacol Ther. 2015 Apr;41(7):613-23. doi: 10.1111/apt.13083. Epub 2015 Feb 4. Review.

12.

Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.

Warman A, Straathof JW, Derijks LJ.

Eur J Gastroenterol Hepatol. 2015 Mar;27(3):242-8. doi: 10.1097/MEG.0000000000000279.

PMID:
25569569
13.

Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience.

Yamada S, Yoshino T, Matsuura M, Minami N, Toyonaga T, Honzawa Y, Tsuji Y, Nakase H.

BMC Gastroenterol. 2014 Apr 23;14:80. doi: 10.1186/1471-230X-14-80.

14.

Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial.

Buhl SS, Steenholdt C, Brynskov J, Thomsen OØ, Bendtzen K, Ainsworth MA.

BMJ Open. 2014 Dec 18;4(12):e005887. doi: 10.1136/bmjopen-2014-005887.

15.

Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up.

Caviglia R, Ribolsi M, Rizzi M, Emerenziani S, Annunziata M, Cicala M.

World J Gastroenterol. 2007 Oct 21;13(39):5238-44.

16.

Infliximab therapy in pediatric patients 7 years of age and younger.

Kelsen JR, Grossman AB, Pauly-Hubbard H, Gupta K, Baldassano RN, Mamula P.

J Pediatr Gastroenterol Nutr. 2014 Dec;59(6):758-62. doi: 10.1097/MPG.0000000000000533.

PMID:
25419596
17.

Efficacy of infliximab in acute severe ulcerative colitis: a single-centre experience.

Halpin SJ, Hamlin PJ, Greer DP, Warren L, Ford AC.

World J Gastroenterol. 2013 Feb 21;19(7):1091-7. doi: 10.3748/wjg.v19.i7.1091.

18.

Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.

Absah I, Faubion WA Jr.

Inflamm Bowel Dis. 2012 Aug;18(8):1488-92. doi: 10.1002/ibd.21885. Epub 2011 Aug 31.

PMID:
21882301
19.

Factors associated with durable response to infliximab in Crohn's disease 5 years and beyond: a multicenter international cohort.

Juillerat P, Sokol H, Froehlich F, Yajnik V, Beaugerie L, Lucci M, Burnand B, Macpherson AJ, Cosnes J, Korzenik JR.

Inflamm Bowel Dis. 2015 Jan;21(1):60-70. doi: 10.1097/MIB.0000000000000225.

PMID:
25517594
20.

Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.

Molander P, Sipponen T, Kemppainen H, Jussila A, Blomster T, Koskela R, Nissinen M, Rautiainen H, Kuisma J, Kolho KL, Färkkilä M.

J Crohns Colitis. 2013 Oct;7(9):730-5. doi: 10.1016/j.crohns.2012.10.018. Epub 2012 Nov 21.

PMID:
23182163

Supplemental Content

Support Center